Ruperto N, et al. - In patients with active systemic juvenile idiopathic arthritis (JIA), researchers assessed the long-term efficacy and safety of canakinumab treatment. Using JIA American College of Rheumatology 50/70/90 criteria, they found that the 2-year response rates 62%, 61%, and 54%, respectively. Findings indicated that the response to canakinumab therapy was sustained and associated with substantial glucocorticoid dose reduction or discontinuation as well as a relatively low retention-on-treatment rate. The investigators did not observe any new safety findings on long-term use of canakinumab.